Editas Medicine (EDIT) Assets (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Assets of $186.5 million for Q4 2025, down 45.39% year-over-year from $341.6 million in Q4 2024, and down 7.54% quarter-over-quarter from $201.8 million in Q3 2025.
Editas Medicine (EDIT) Assets (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Assets for 11 consecutive years, with $186.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets fell 45.39% year-over-year to $186.5 million; the TTM figure through Dec 2025 stood at $186.5 million (down 45.39% YoY), while the FY2025 annual figure was $186.5 million, down 45.39% from the prior year.
- Assets retreated to $186.5 million in Q4 2025 per EDIT's latest filing, from $201.8 million in the prior quarter.
- Across five years, Assets topped out at $780.3 million in Q1 2021 and bottomed at $186.5 million in Q4 2025.
- Historically, Assets has averaged $477.3 million across 5 years, with a median of $501.9 million in 2023.
- Annual changes were most pronounced in 2021 — Assets surged 67.18% — and 2025, when it tumbled 45.39%.
- Editas Medicine's Assets stood at $677.5 million in 2021, then retreated by 24.08% to $514.3 million in 2022, then declined by 2.95% to $499.2 million in 2023, then sank by 31.57% to $341.6 million in 2024, then sank by 45.39% to $186.5 million in 2025.
- Business Quant data shows EDIT's Assets at $186.5 million in Q4 2025, $201.8 million in Q3 2025, and $210.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 186.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 186.53 Mn |
| Sep 30, 2025 | 201.75 Mn |
| Jun 30, 2025 | 210.58 Mn |
| Mar 31, 2025 | 263.65 Mn |
| Dec 31, 2024 | 341.59 Mn |
| Sep 30, 2024 | 327.57 Mn |
| Jun 30, 2024 | 384.80 Mn |
| Mar 31, 2024 | 440.35 Mn |
| Dec 31, 2023 | 499.15 Mn |
| Sep 30, 2023 | 504.65 Mn |
| Jun 30, 2023 | 541.95 Mn |
| Mar 31, 2023 | 464.11 Mn |
| Dec 31, 2022 | 514.32 Mn |
| Sep 30, 2022 | 531.03 Mn |
| Jun 30, 2022 | 580.83 Mn |
| Mar 31, 2022 | 623.11 Mn |
| Dec 31, 2021 | 677.48 Mn |
| Sep 30, 2021 | 717.02 Mn |
| Jun 30, 2021 | 755.88 Mn |
| Mar 31, 2021 | 780.29 Mn |